These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33239417)

  • 1. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
    Rozenblit M; Huang R; Danziger N; Hegde P; Alexander B; Ramkissoon S; Blenman K; Ross JS; Rimm DL; Pusztai L
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.
    Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
    Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
    Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
    Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
    Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis.
    Boman C; Zerdes I; Mårtensson K; Bergh J; Foukakis T; Valachis A; Matikas A
    Cancer Treat Rev; 2021 Sep; 99():102257. PubMed ID: 34237488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma.
    Hoda RS; Brogi E; Dos Anjos CH; Grabenstetter A; Ventura K; Patil S; Selenica P; Weigelt B; Reis-Filho JS; Traina T; Robson M; Norton L; Wen HY
    Mod Pathol; 2020 Nov; 33(11):2221-2232. PubMed ID: 32612248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
    Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
    Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
    Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
    PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
    Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
    BMC Cancer; 2021 Mar; 21(1):239. PubMed ID: 33676425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma.
    Kim HS; DO SI; Kim DH; Apple S
    Anticancer Res; 2020 Mar; 40(3):1487-1494. PubMed ID: 32132048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
    Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
    J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
    Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
    Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
    Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
    Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer.
    Moutafi MK; Tao W; Huang R; Haberberger J; Alexander B; Ramkissoon S; Ross JS; Syrigos K; Wei W; Pusztai L; Rimm DL; Vathiotis IA
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
    Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
    Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
    Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
    Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
    Ahn SG; Kim SK; Shepherd JH; Cha YJ; Bae SJ; Kim C; Jeong J; Perou CM
    Breast Cancer Res Treat; 2021 Jul; 188(1):165-178. PubMed ID: 33770313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
    Li Y; Vennapusa B; Chang CW; Tran D; Nakamura R; Sumiyoshi T; Hegde P; Molinero L
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):258-264. PubMed ID: 33030848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.
    Peg V; López-García MÁ; Comerma L; Peiró G; García-Caballero T; López ÁC; Suárez-Gauthier A; Ruiz I; Rojo F
    Future Oncol; 2021 Apr; 17(10):1209-1218. PubMed ID: 33289433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.